Applied DNA Sciences Inc. said its normalized net income for the fiscal second quarter ended March 31 amounted to a loss of 9 cents per share, compared with the S&P Capital IQ consensus estimate of a loss of 10 cents per share.
The per-share loss increased 32.6% year over year from 7 cents.
Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of $2.2 million, compared with a loss of $1.2 million in the prior-year period.
Total revenue fell 62.3% year over year to $573,320 from $1.5 million, and total operating expenses increased 18.3% year over year to $4.0 million from $3.4 million.
Reported net income came to a loss of $3.5 million, or a loss of 14 cents per share, compared to a loss of $1.9 million, or a loss of 11 cents per share, in the year-earlier period.